The Scientist

» drug development

Most Recent

image: Toward Targeted Therapies for Autoimmune Disorders

Toward Targeted Therapies for Autoimmune Disorders

By | June 1, 2016

Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.

1 Comment

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Another Fatal-Disease Drug in Limbo

Another Fatal-Disease Drug in Limbo

By | April 26, 2016

A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.

0 Comments

image: First Data from Anti-Aging Gene Therapy

First Data from Anti-Aging Gene Therapy

By | April 25, 2016

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

8 Comments

image: Zooming In on an Antidepressant Target

Zooming In on an Antidepressant Target

By | April 6, 2016

Structural studies reveal how SSRI drugs bind to the human serotonin transporter.

0 Comments

image: Another Drug Price Hike

Another Drug Price Hike

By | March 28, 2016

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

0 Comments

image: Cannabis-Based Drug for Epilepsy

Cannabis-Based Drug for Epilepsy

By | March 14, 2016

A marijuana-derived compound shows continued success in treating children with a rare form of the seizure disorder. 

0 Comments

image: Desperately Seeking Shut-Eye

Desperately Seeking Shut-Eye

By | March 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Things That Go Bump

Things That Go Bump

By | March 1, 2016

Scientists still don’t know why animals sleep or how to define the ubiquitous behavior.

2 Comments

image: Shire to Buy Baxalta for $32 Billion

Shire to Buy Baxalta for $32 Billion

By | January 12, 2016

The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.

0 Comments

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS